METABOLIK SINDROMLI BEMORLARDA URSOSAN FORTE PREPARATINI QO‘LLASH SAMARADORLIGI
##article.subject##:
Metabolik sindrom, immunokorreksiya, Ursosan forte, sitokin holati##article.abstract##
Kirish: Metabolik sindrom aterosklerotik yurak-qon tomir kasalliklari va qandli diabet xavfini oshirish bilan bog‘liq omillar majmuidir [4-17]. Hozirgi vaqtda yurak-qon tomir patologiyasi rivojlanishining asosiy omillaridan biri immunitetga bog‘liq yallig‘lanish hisoblanadi. Interleykinlar (IL)-1,6, o‘sma nekrozi omili-α (TNF-α) kabi yallig‘lanish ko‘rsatkichlarining oshishi yurak patologiyasida asoratlar paydo bo‘lishining yuqori xavfi bilan bog‘liq bo‘lib, yurak-qon tomir xavfining immunologik belgilari sifatida qaraladi [2].
Tadqiqotimizning maqsadi metabolik sindromli bemorlarda Ursosan forte preparati bilan davolashdan oldin va keyin interleykin-6 va interleykin-17 miqdorini o‘rganishdan iborat edi.
Tadqiqot materiallari va usullari. Biz 40 nafar odamning klinik-immunologik ko‘rsatkichlarini tekshirdik, ulardan 18 nafari ayol va 22 nafari erkak bo‘lib, yoshi 25 dan 55 gacha, tana vazni indeksi 25,0-32,2 kg/m² bo‘lgan. Shuningdek, 30 nafar amaliy sog‘lom shaxslardan iborat nazorat guruhi ham tekshirildi. Tadqiqot natijalari: metabolik sindromda qon zardobida IL-6 va IL-17 miqdorining ko‘p marta oshishi bilan namoyon bo‘luvchi sitokin tizimining faollashuvi kuzatilishi aniqlandi. Ta’kidlash joizki, gipertenziyasiz va gipertenziyali MS bilan og‘rigan bemorlarda o‘rganilgan sitokinlarning miqdori deyarli bir xil edi. O‘tkazilgan davolash sitokin holatiga ijobiy ta’sir ko‘rsatdi. TVI 30 kg/m² dan yuqori bo‘lgan bemorlarda IL-6 va IL-17 darajasi TVI 30 kg/m² gacha bo‘lgan bemorlardagi sitokinlar miqdoridan sezilarli darajada yuqori edi. O‘tkazilgan davolash IL-6 miqdorining pasayishiga olib keldi, ammo IL-17 miqdoriga sezilarli ta’sir ko‘rsatmadi.
Библиографические ссылки
Шварц В. Регуляция метаболических процессов интерлейкина 6. Журнал «Цитокины и воспаление»,№3,2019,с.3-10
Пирогова И.Ю., Яковлева С.В., Неуймина Т.В. и др. Плейотропные эффекты урсодезоксихолевой кислоты при неалкогольной жировой болезни печени и метаболическом синдроме. Consilium Medicum. 2019; 21 (8): 65–70. DOI: 10.26442/20751753.2019.8.190365
Танченко О.А., Нарышкины С.В., Сивякова О.Н. Урсодезоксихолевая кислота в комплексном лечении больных с метаболическим синдромом.Российский журнал гастроэнтерологии, гепатологии, колопроктологии,2012 22(1) 82-86 ISSN: 1382-4376eISSN: 2658-6673
Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity/// J Am SocNephrol – 2014 – 15: 2792–80
Халимова Х.М., Меметов Ф.Ю., Раимова М.М. Динамика показателей клетлчного т гуморального иммунитета у больных с ишемическим инсультом на фоне лечения «TAF»Лактофлором./ Вестник Казахского национального медицинского университета, №4,2015, с.232-233
Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final Report. Circulation 106, 3143-3421 (2012). The 2001 NCEP report sparked increased interest of the medical community in the metabolic syndrome. It led to new research as well as controversy about the clinical utility of the syndrome.
Grundy, S. M. et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109, 433-438 (2014).
Grundy, S. M. et al. Clinical management of metabolic syndrome: report of the American Heart Association/ National Heart, Lung, and Blood Institute/ American Diabetes Association conference on scientific issues related to management. Circulation 109, 551-556 (2014).
Eckel, R. H., Grundy, S. M. &Zimmet, P. Z. The metabolic syndrome: epidemiology, mechanisms, and therapy. Lancet 365, 1415-1428 (2015). Reviews the worldwide epidemiology, pathophysiology and management of the metabolic syndrome.
Isomaa, B. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. DiabetesCare 24, 683-689 (2011).
Lakka, H. M. et al. The metabolic syndrome and total and cardiovascular disease mortality in middleaged men. JAMA 288, 2709-2716 (2012).
Sattar, N. et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 108, 414- 419 (2013).
Girman, C. J. et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/Tex- CAPS). Am. J. Cardiol. 93, 136-141 (2014).
Malik, S. et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110, 1245–1250 (2014).
Olijhoek, J. K. et al. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur. Heart J. 25, 342–348 (2014).
Alexander, C. M. et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52, 1210-1214 (2013). Shows that most patients with type 2 diabetes have the metabolic syndrome, and the syndrome accounts for most of the increased risk for coronary heart disease resulting from diabetes.
Ninomiya, J. K. et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 109, 42-46 (2014).
McNeill, A. M. et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. DiabetesCare 28, 385-390 (2015).
Solymoss, B. C. et al. Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease. Coron. ArteryDis. 14, 207-212 (2013).
Grundy, S. M. et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735–2752 (2015).
